Stefano Navarro: Partial GPVI Downregulation Shows Promise for Safer Antithrombotic Therapy
Stefano Navarro, Postdoctoral Researcher at Rudolf Virchow Center of University of Würzburg, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Signal Transduction and Targeted Therapy, adding:
“What if antiplatelet therapy does not always need to completely block a platelet receptor?
This is the idea we explored in our new article in Signal Transduction and Targeted Therapy.
Instead of fully blocking or downregulating the collagen/fibrin (fibrinogen) receptor Glycoprotein (GP) VI, we asked whether its surface expression could be ‘tuned down’ to an intermediate level.
By partially downregulating GPVI, we generated a low-density GPVI phenotype (GPVILO) in which the adhesive function of the receptor was largely preserved, while its intracellular signaling was selectively dampened.
This uncoupling of adhesion from signaling was sufficient to protect from thrombosis and thrombo-inflammation, while preserving hemostasis in our experimental models.
Many thanks to all co-authors and collaborators who contributed to this work, and especially to Bernhard Nieswandt for his guidance throughout the project.”
Title: Partial downregulation of platelet glycoprotein VI by low affinity antibodies confers sustained and safe antithrombotic protection
Authors: Stefano Navarro, Sarah Beck, Sabrina I. Bonfiglio, Ernesto J. Cuenca-Zamora, Lukas J. Weiß, Marijke Kuijpers, Johan Heemskerk, David Stegner, Bernhard Nieswandt
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 3, 2026, 14:55Rabiah Alnoshan: The Importance of Pulse Examination in Acute Limb Ischemia
-
Jul 3, 2026, 14:44Carrie Gillies: Personal Experience Reinforces the Need for Timely DVT Diagnosis
-
Jul 3, 2026, 14:30Munazza Sikandar: Comparing Figure-of-Eight Sutures and Manual Compression for Safer Post-Ablation Care
-
Jul 3, 2026, 13:31Javed Anees: TIA is a Medical Emergency – Not a Benign Warning
-
Jul 3, 2026, 12:46Heghine Khachatryan: 2026 AHA Guideline on the Management of CKM Syndrome
-
Jul 3, 2026, 12:32Shadi Tabibian: Beyond Bleeding – Women Living with von Willebrand Disease
-
Jul 3, 2026, 09:33Abdul Mannan: Not All Type 1 VWD Starts in the VWF Gene
-
Jul 3, 2026, 09:18Aryabhatta Sadhu: Sickle Cell Crisis – When Diagnostics Should Change Therapy
-
Jul 3, 2026, 05:55New Evidence Supports Chromogenic Assays After Hemophilia A Gene Therapy – JTH